FDA Drug Recall Announcements

For a complete list of U.S. Food and Drug Administration notices, please visit the FDA’s website for information on all FDA recalls, market withdrawals, and safety alerts.

Click the links below to learn more about the FDA’s latest recalls:

Eugia US LLC Issues Voluntary Nationwide Recall of Methocarbamol Injection, USP 1000 mg/10 mL Due to Presence of White Particles, FDA published March 28, 2024

Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution, FDA published March 12, 2024  

Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® 30 mg Due to a Mislabeled Package During Manufacturing, FDA published January 25, 2024

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, 8.4% Sodium Bicarbonate Injection, and Atropine Sulfate Injection Due to the Potential Presence of Glass Particulate Matter, FDA published December 26, 2023

Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 2 Lots of Tydemy™ Due to Out of Specification Results at the 12-month Stability Time Point, FDA Published July 31, 2023

Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) Due to Container Defect, FDA published July 7, 2023

The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Dronabinol Capsules, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules, 20 mg Due to Label Mix-up, FDA published June 14, 2023

Akorn Issues Voluntary Nationwide Recall of Various Human and Animal Drug Products Within Expiry Due to Company Shutdown, FDA published May 04, 2023